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Targeting COX-2 and EP4 to control tumor growth,
angiogenesis, lymphangiogenesis and metastasis to
the lungs and lymph nodes in a breast cancer model
Xiping Xin1, Mousumi Majumder1, Gannareddy V Girish1, Vik Mohindra1, Takayuki Maruyama2 and
Peeyush K Lala1,3

We reported that cyclo-oxygenase (COX)-2 expression in human breast cancer stimulated cancer cell migration and
invasiveness, production of vascular endothelial growth factor (VEGF)-C and lymphangiogenesis in situ, largely from
endogenous PGE2-mediated stimulation of prostaglandin E (EP)1 and EP4 receptors, presenting them as candidate
therapeutic targets against lymphatic metastasis. As human breast cancer xenografts in immuno-compromised mice have
limitations for preclinical testing, we developed a syngeneic murine breast cancer model of spontaneous lymphatic
metastasis mimicking human and applied it for mechanistic and therapeutic studies. We tested the roles of COX-2 and EP
receptors in VEGF-C and -D production by a highly metastatic COX-2 expressing murine breast cancer cell line C3L5.
These cells expressed all EP receptors and produced VEGF-C and -D, both inhibited with COX-2 inhibitors or EP4 (but not
EP1, EP2 or EP3) antagonists. C3H/HeJ mice, when implanted SC in both inguinal regions with C3L5 cells suspended in
growth factor-reduced Matrigel, exhibited rapid tumor growth, tumor-associated angiogenesis and lymphangiogenesis
(respectively measured with CD31 and LYVE-1 immunostaining), metastasis to the inguinal and axillary lymph nodes and
the lungs. Chronic oral administration of COX-1/COX-2 inhibitor indomethacin, COX-2 inhibitor celecoxib and an EP4
antagonist ONO-AE3-208, but not an EP1 antagonist ONO-8713 at nontoxic doses markedly reduced tumor growth,
lymphangiogenesis, angiogenesis, and metastasis to lymph nodes and lungs. Residual tumors in responding mice revealed reduced VEGF-C and -D proteins, AkT phosphorylation and increased apoptotic/proliferative cell ratios consistent
with blockade of EP4 signaling. We suggest that EP4 antagonists deserve clinical testing for chemo-intervention of
lymphatic metastasis in human breast cancer.
Laboratory Investigation (2012) 92, 1115–1128; doi:10.1038/labinvest.2012.90; published online 28 May 2012
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Cyclo-oxygenase (COX)-2, an inflammation-associated
enzyme is believed to be a key factor during tumor initiation
in tissues subjected to chronic inflammation.1 Furthermore,
COX-2 overexpression is a signature as well as a major
determinant of tumor progression and metastasis in a variety
of cancers including breast cancer.1–3 In mice, transgenic
overexpression of COX-2 induces mammary neoplasia,4 and
its pharmacological inhibition5 or genetic deletion6 suppresses
HER-2-induced mammary cancer development. COX-2 expression in human breast cancer is correlated with reduced
survival, as well as other indicators of poor prognosis, such as

increased tumor size, high tumor grade, negative hormone
receptor status, HER-2 overexpression,7 angiogenesis,8 metastasis to lymph nodes8,9 and other organs.10 In a case–control
study in women, use of selective COX-2 inhibitors was associated with a 71% reduction in breast cancer risk.11 Our laboratory had shown that tumor-derived PGE2 frequently
resulting from elevated COX-2 expression promotes breast
cancer progression by multiple mechanisms: an inactivation of
host antitumor immune cells,12 a stimulation of tumor cell
migration, invasiveness and tumor-associated angiogenesis13–16
as well as lymphangiogenesis resulting from an upregulation of
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vascular endothelial growth factor (VEGF)-C,17 thereby promoting lymphatic metastasis. In these studies, COX-2-mediated promotion of migratory,15 invasive16 and VEGF-C
upregulatory17 functions were at least in part due to stimulation of PGE receptors prostaglandin E (EP)4, and to a minor
extent EP1, expressed by breast cancer cells.
Whether lymphatic metastasis in human breast cancer
occurs via pre-existing or newly formed lymphatics has been
a subject of debate.18–20 However, recent evidence clearly
reveals that expression of VEGF-C9,17,21 or VEGF-D22 in
human breast cancer in situ is strongly correlated with lymphangiogenesis, lympho-vascular invasion and lymphatic
metastasis. In addition to its role in promoting lymphangiogenesis, we found that VEGF-C production by breast
cancer cells served as an autocrine stimulus for their motility
by binding to a diverse group of VEGF-C receptors.23
Although VEGF-C production and lymphangiogenesis was a
direct consequence of COX-2 expression in human breast
cancer,17 we found that HER-2, often co-expressed
with COX-2 in human breast cancer, had no direct role in
VEGF-C upregulation or lymphangiogenesis, and that its
role, if any, was COX-2 dependent.21
The facts that COX-2 is overexpressed in about half of
breast cancer specimens7 inclusive of DCIS24 and invasive
carcinomas,21 and has multiple roles in breast cancer progression and metastasis, make this molecule a reasonable
therapeutic target. Recent safety concerns related to the cardiovascular side effects of high dose COX-2 inhibitors25,26
have led to the search for alternative targets downstream of
COX-2, which would spare the vaso-protective prostacyclins.
The PGE2 receptors (EP1, EP2, EP3 and EP4) may present as
attractive alternatives because of their differential signaling
abilities resulting from their coupling with different G proteins. For example, EP1 is coupled with Gq, typically stimulating [Ca þ þ ]i ; EP2 and EP4 are coupled with Gs,
stimulating adenylate cyclase (AC) followed by PKA activity;
EP3 is typically coupled with Gi, thus inhibiting AC, although
some EP3 splice variants differ in their activity.27 EP4, unlike
EP2, can also activate an additional phosphatidylinositol
3-kinase (PI3K) pathway leading to AkT activation.28,29
Our observation that COX-2-mediated stimulation of
VEGF-C and lymphangiogenesis in situ resulted largely from
endogenous PGE2-mediated stimulation of EP4 and to a
smaller extent EP1 receptors on human breast cancer cells,17
presented these receptors as candidate therapeutic targets
against lymphatic metastasis. In view of the findings that
suppression of host antitumor immune mechanisms may
partially contribute to PGE2-mediated promotion of breast
cancer progression,12,30–32 using human breast cancer xenografts in immuno-compromised mice was considered less
than ideal for a preclinical testing of these targets. For this
reason, this study was designed to develop a syngeneic
COX-2 expressing murine breast cancer model of spontaneous lymphatic metastasis mimicking human and test it for
therapy with COX-2 inhibitors and selective EP antagonists.
1116

This model allowed us to conduct mechanistic studies in vitro
and therapeutic as well as mechanistic studies in vivo, leading
to the conclusion that EP4 is an excellent therapeutic target.
MATERIALS AND METHODS
Cell Lines
C3L5 is a COX-2 expressing, PGE2 secreting murine breast
cancer cell line produced in our laboratory, the PGE2
secreting ability primarily attributed to COX-2.14,16 It is a
lung metastasis derivative of the C3 line, which was clonally
derived from a spontaneous mammary adenocarcinoma in
a C3H/HeJ retired breeder female mouse.12 Persistent metastatic ability of this clone was gained by five cycles of in vivo
passage and selection of lung micro-metastases.33 Cells were
maintained in high glucose DMEM (GIBCO, Grand Island,
NY, USA) supplemented with 5% fetal bovine serum, 100 U/
ml penicillin G and 100 mg/ml streptomycin in a humidified
incubator with 5% CO2 at 37 1C.
Drugs
Indomethacin (non-selective COX-1/COX-2 inhibitor, used
for in vitro and in vivo studies) was obtained from Sigma
(Oakville, ON, Canada). NS-398 (selective COX-2 inhibitor,
used for in vitro studies) was from Cayman Chemical, Ann
Arbor, MI, USA. AH 6809 (EP2 antagonist, used for in vitro
studies) was from Biomol (Plymouth Meeting, PA, USA).
Celecoxib (selective COX-2 inhibitor, used for in vitro and
in vivo studies) was a gift of Pfizer, Groton, CT, USA. ONO8713, ONO-AE3-240 and ONO-AE3-208 (selective antagonists for EP1, EP3 and EP4, respectively, used for in vitro and
in vivo studies) were generously provided by ONO Pharmaceuticals, Osaka, Japan. The structure, binding affinity,
selectivity and pharmacokinetic properties of the EP
antagonists have been characterized by ONO pharmaceuticals.34,35 For in vitro treatments, NS-398 and indomethacin
were dissolved in 0.13% ethanol in PBS, and EP antagonists
in 0.2% DMSO in PBS. For treating tumor transplanted
mice, the details of all the vehicles used to dissolve or
administer the drugs are presented later. For all treatments
in vitro or in vivo, respective vehicles served as the control.
Real-Time qPCR
Total RNA from cells was extracted with the PerfectPure RNA
Cultured Cell Kit (5 PRIME, Gaithersburg, MD, USA) and
cDNA was synthesized with the qScript cDNA synthesis kit
(Quanta Biosciences, Gaithersberg, MD, USA) in a T-Gradient thermocycler (Biometra GmbH, Gottingen, Germany).
Quantitative RT-PCR (q-PCR) for VEGF-C, VEGF-D and
GAPDH (housekeeping gene) was performed in triplicate
using a Corbett Thermocycler (Corbett Research, Mortlake,
Australia) and PerfeCTa SYBR green supermix (Quanta
Biosciences). All primers were synthesized at the University
of Western Ontario Oligo Factory as follows: VEGF-C primer
sequence: 50 -GTATAGATGTGGGGAAGGAGT-30 (forward),
50 -GACACTGTGGTAATGTTGCTG-30 (reverse); VEGF-D
Laboratory Investigation | Volume 92 August 2012 | www.laboratoryinvestigation.org
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primer sequence: 50 -GTAGCTGCCTGGAAACAACTG-30
(forward), 50 -GGTCCTCTGCCATTCTTCATC-30 (reverse);
GAPDH primer sequence: 50 -GTAGCCGTATTCATTGTCAT30 (forward), 50 -AATGCATCCTGCACCACCAA-30 (reverse).
Primers were checked for appropriate product size by PCR
with murine cDNA. Fold changes in VEGF-C and VEGF-D
mRNA following treatment of cells were expressed relative to
GAPDH mRNA using delta Ct method.

Knock Down of EP4 Receptor
EP4 siRNA products consisted of pools of three to five targetspecific 19–25 nucleotide siRNAs designed to knockdown
mouse EP4 gene expression (SC-40174, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and silence select negative
control siRNA (Cat. No: 4390843, Ambion) was used as EP4SC siRNA. Cells were incubated in a six-well cell culture
plate, at a count of 5  104 cells per well. C3L5 cells were
transfected with experimental and negative control siRNA
(scrambled siRNA), respectively, in a separate well using
JetPrime Polyplus DNA transfection reagent (Cat. No. 11407) using the DMEM medium with 10% FBS and incubated
for 72 h. C3L5 cells were washed with PBS and total RNA
from respective treated cells was extracted with the PerfectPure RNA Cultured Cell Kit (5 PRIME) and cDNA was
synthesized with the qScript cDNA synthesis kit (Quanta
Biosciences). Transcript levels for GAPDH, VEGF-C and
VEGF-D for each set of cDNA were quantified using respective primers as described above. EP4, VEGF-C and
VEGF-D mRNA following treatment of cells were expressed
relative to GAPDH using delta Ct method.

Western Blot Analysis
In all, 40 mg total protein from cell lysates were run under
reducing conditions on a SDS-PAGE gel (10%) and transferred onto Immobilon PVDF membrane-FL (Millipore,
Billerica, MA, USA). Polyclonal goat anti-mouse VEGF-C
(1:200), rabbit anti-mouse VEGF-D (1:200) and monoclonal
mouse anti-mouse b-actin (Santa Cruz Biotechnology) and
polyclonal rabbit antibodies against EP1, EP2, EP3 or EP4
(1:200 dilution; Cayman Chemical) were used for immunoblotting, followed by incubation with IRDye polyclonal
secondary antibodies from LI-COR (Lincoln, NE, USA):
donkey anti-goat (1:5000), goat anti-rabbit (1:5000) and
donkey anti-mouse (1:20 000) as appropriate. Membranes
were scanned on an Odyssey infrared imaging system (LICOR). For analysis of tumor tissues, samples were snapfrozen in liquid nitrogen and powdered with mortar and
pestle before addition of lysis buffer. Samples were then
homogenized with a polytron, and western blot was performed as described above for VEGF-C and VEGF-D and
additionally total AkT and phospho-AkT (Thr-308) using
rabbit polyclonal antibodies (1:1000) from Cell Signaling,
Danvers, MA, USA.
www.laboratoryinvestigation.org | Laboratory Investigation | Volume 92 August 2012

Enzyme-Linked Immunosorbent Assay (ELISA)
Cells were serum starved for 48 h and supernatant centrifuged at 4500  g for 8 min to remove debris and ELISA for
VEGF-C performed with the manufacturer’s protocol
(USCNLIFE Sciences and Technology, Wuhan, China). This
could not be done for mouse VEGF-D because of unavailability of a suitable antibody or reproducible ELISA kit.
Mice
Six-week-old female C3H/HeJ mice were obtained from the
Jackson Laboratory and allowed to acclimatize for 2–3 weeks,
maintained on standard mouse chow and tap water (unless
otherwise indicated) on a 12-h light–dark cycle, and treated
in accordance with the guidelines set by the Canadian
Council on Animal Care.
Tumor Transplantation and Measurements of Tumor
Progression
Levels of tumor growth, tumor-associated angiogenesis and
lymphangiogenesis were measured with an in vivo assay devised in our laboratory14,36 in which tumor cells suspended in
growth factor-reduced Matrigel were implanted SC, allowing
ingrowths of capillaries and lymphatics from pre-existing
vasculature. Originally devised for measuring the kinetics of
tumor-associated angiogenesis,36 our pilot studies revealed
that this in vivo assay was also exquisitely suited for measuring tumor-associated lymphangiogenesis. Mice were randomized into treatment groups and received subcutaneous
implants of 5  104 C3L5 cells suspended in growth factorreduced Matrigel (3.5 mg Matrigel in 0.5 ml DMEM) (BD
Biosciences, Bedford, MA, USA) in both inguinal mammary
regions. Some animals received implants of Matrigel alone, to
serve as negative controls for angiogenesis or lymphangiogenesis. Treatment regimens included indomethacin (12 mg/
ml drinking water), celecoxib (125 mg/kg by oral gavage,
b.i.d.), ONO-8713 and ONO AE3-208 (5 mg/kg by oral gavages, b.i.d.) or their vehicles alone (controls). Celecoxib was
dissolved in 0.5% methylcellulose (Sigma). ONO-8713 and
ONO-AE3-208 were dissolved in 0.003 N NaOH. The dosage
and vehicles for using these drugs were guided by earlier
reports for indomethacin,14 celecoxib37 and EP antagonists.38
The water intake was measured daily to ensure that drug
intake by the oral route did not affect their hydration compared with control mice receiving vehicles alone. Mice were
killed by exposure to halothane followed by cervical dislocation, at 8, 12 and 16 days (n ¼ 8 for each treatment
with drugs or corresponding vehicle per day). On retrieval of
the Matrigel implants (two per mouse), their weights
and dimensions (maximum and minimum diameters) were
recorded and gross morphology photographed. Tumors were
then sliced in halves, each half fixed or frozen for further
histological or immuno-histological analysis. Tumor-draining inguinal and distant axillary lymph nodes were removed
and their dimensions measured before fixing them for histopathology.
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Scoring Metastases
Metastatic lung colonies were scored as previously reported,13
with a modification as follows. Lungs were inflated in situ
with Bouin’s fixative. Surface colonies on intact lungs being
too small to be counted with a dissecting microscope at
earlier time points, micro-metastases were scored in hematoxylin and eosin (H&E)-stained coronal sections through
mid-trachea (planned to obtain the maximal surface area of
both lungs) in paraffin-embedded tissues. This provided a
standardized method of scoring micro-metastases in both
lungs. The micro-metastases were scanned and counted at
 100 magnification, and verified at  400 magnification,
under a Laborlux K microscope (Leitz, Germany). Mean and
median scores of lung micro-metastases were based on eight
mice per group, with each score acquired from counts of all
lobes. Metastasis to lymph nodes were identified histologically in H&E-stained sections of paraffin-embedded tissues,
and scanned at  100 magnification and verified at higher
(  200 and  400) magnifications. Tumor-draining inguinal
lymph nodes were assessed as sites of regional lymph node
metastasis, and axillary nodes on each side (the first node
receiving lymph drainage from the inguinal node) as sites of
distant lymph node metastasis. As no specific marker was
used for tumor cells, metastasis at the single cell level or as
small cell clusters could not be accurately determined, until
cancer cells appeared as overt colonies. Both pulmonary and
lymphatic metastases were scored by two independent observers with o7% variation and verified rigorously by one
author (PKL), a trained histopathologist.
Measurements of Angiogenesis and Lymphangiogenesis
In all, 8 mm thick frozen sections of Matrigel implants were
fixed in methanol for 3 min and then in acetone for 3 min,
both at 4 1C. All of the subsequent steps were performed at
room temperature. Sections were air-dried for 1 h, rehydrated
for 10 min in PBS, followed by treatment with 2% BSA in
PBS for 20 min to block nonspecific antibody binding. Sections were then incubated for 1 h with rabbit anti-mouse
LYVE-1 (Upstate Biotechnologies, Lake Placid, NY, USA;
1:200) and rat anti-mouse CD31 (Caltag Laboratories, Advanced Medical Sciences, Bangkok, Thailand, 1:1000) antibodies, followed by normal mouse serum (1%) for 10 min to
block nonspecific cross-reactivity of secondary antibodies
with mouse proteins. Sections were then incubated for
30 min with goat anti-rabbit Alexa Fluor 488 and donkey
anti-rat Alexa Fluor 594 secondary antibodies (Molecular
Probes, Burlington, ON, Canada; 1:1000, washed with PBS,
drained, and mounted with Vectashield solution (Vector
Laboratories, Burlington, ON, Canada). The sections from all
tumors were first scanned at low magnification (  250)
under a BX51 microscope (Olympus) to identify the most
vascular areas of the tumor. Adjacent sections of fixed tissues
stained with Masson’s Trichrome36 visualized under bright
field microscopy provided a map to locate vessels within the
peritumoral stroma as well as within the tumors. With this
1118

method, capillaries devoid of red cells could not be adequately discriminated between blood or lymphatic capillaries.
Microvessel density (MVD) representing blood vessels and
lymphatic vessel density (LVD) were assessed in dual immunostained sections of frozen tissues as reported,36,39 with
the following modification. Three hotspots per tumor (48 per
group per day) were examined at  400 magnification, and
scored after setting the threshold for background, using the
Image-J software (NIH, USA). The mean values for MVD
and LVD were computed as the staining indices for CD31
(red) and LYVE-1 (green), respectively.
Computing Apoptotic/Proliferative Cell Ratios
Serial 8 mm thick deparaffinized histological sections of paraffin-embedded tumor tissues from vehicle-treated and drugtreated mice were immunostained for proliferative cell marker Ki67 (monoclonal rat anti-mouse antibody from Dako
Canada, Burlington, ON, Canada, applied at 1:200 dilution
in PBS–BSA overnight at 4 1C) and apoptotic cells by dUTP
nick end labeling (TUNEL apoptosis detection kit and protocol from Trevigen, Gaithersburg, MD, USA) after proteinase K antigen retrieval. Ki67 was detected with biotinlabeled secondary antibody treatment (1:2000), followed by
Streptavidin-Texas red (red fluorescence). TUNEL staining
gave green fluorescence. The ratios of apoptotic/proliferative
cells were determined by image analysis (Image-J program).
Statistical Analysis
Data were analyzed using the Sigma Stat (version 3.5, Systat,
San Jose, CA, USA) program employing two-way ANOVA
and tested by Student’s t-test, with one exception. To compare lung micro-metastases between control (vehicle-treated)
and drug-treated mice, the data were also subjected to the
non-parametric Wilcoxon rank sum test. A P-value of o0.05
was considered as significant.
RESULTS
COX-2 Inhibitors and EP4 Antagonist reduce VEGF-C and
VEGF-D Production by C3L5 Cells
C3L5 cells expressed high levels of COX-2 (Figure 1a) and
released PGE2 in serum-free media, and this release was
blocked equally by treating cells (48 h) with COX-1/COX-2
inhibitor indomethacin (20 mM), COX-2 inhibitors NS-398
(20 mM) or celecoxib (1–10 mM), confirming our earlier
findings14,16 that COX-2 is the primary enzyme responsible
for PGE2 production by the cells (data not shown). VEGF-C
and VEGF-D mRNA and proteins, as detected by qPCR
(Figure 1b) and western blotting (Figure 1f) and secreted
VEGF-C by ELISA (control in Figures 1d and e). C3L5 cells
were cultured for 48 h with indomethacin (20 mM), NS-398
(20 mM), celecoxib (1 mM), a selective EP1 antagonist (EP1A)
ONO-8713 (2 mM); non-selective EP2 antagonist (EP2A) AH
6809 (2 mM); a selective EP3 antagonist (EP3A) ONO-AE3240 (2 mM); a selective EP4 antagonist (EP4A) ONO-AE3208 (2 mM). Treating cells with indomethacin (20 mM), or
Laboratory Investigation | Volume 92 August 2012 | www.laboratoryinvestigation.org
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Figure 1 COX-1/2 and COX-2 inhibitors and EP4 antagonist reduce VEGF-C and VEGF-D production in C3L5 cells. (a) Western blot analysis of proteins
in C3l5 cell lysates revealed expression of COX-2 and all the EP receptors. (b, c) Both COX1/2 and COX-2 inhibitors as well as the EP4 (but not EP1, EP2
and EP3) antagonist suppressed VEGF-C and -D mRNA levels relative to GAPDH mRNA (presented as a fraction of control vehicle-treated cells) as well
as secreted VEGF-C (d, e) measured with ELISA. C3L5 cells express VEGF-C (80 kDa) and VEGF-D (21 kDa) (f, control) measured with western blot, which were
reduced by treatments with COX inhibitors and EP4 (but not EP1) antagonist, as compared with vehicle-treated control cells (f, g). siRNA-mediated
knockdown of EP4 resulted in significant drop in VEGF-C and VEGF-D mRNA (h). Data presented in (a, b), (c, d) and (e, f) are from three different
representative experiments. Data represent means (n ¼ 4)±s.e., *Po0.05, **Po0.01, ***Po0.001.

NS-398 (20 mM) or celecoxib (1 mM) for 48 h suppressed
VEGF-C and VEGF-D mRNA expression (Figure 1b). Similarly, indomethacin and celecoxib treatments suppressed
VEGF-C secretion (Figure 1d), measured with ELISA of the
cell-free supernatants.
EP4 but not other EP Receptors Contribute to VEGF-C
and VEGF-D Production by C3L5 Cells
Figure 1a shows that C3L5 cells express all the EP receptor
(EP1, EP2, EP3 and EP4) proteins as detected by western
blotting. Figure 1c shows that the EP4 antagonist ONO-AE3208, but none of the other EP antagonists, significantly
suppressed the VEGF-C and VEGF-D mRNA expression.
Similarly, as shown in Figure 1e, secreted VEGF-C accumulation in supernatants of C3L5 cells grown for 48 h in serumfree medium was significantly inhibited by treating cells with
the EP4 antagonist, but not EP1, EP2 or EP3 antagonists, as
compared with vehicle (DMSO) treatment alone. Furthermore, treatments with COX inhibitors as well as EP4 but not
other EP antagonists reduced both VEGF-C and VEGF-D
protein levels in C3L5 cell lysates (Figures 1f and g). These
www.laboratoryinvestigation.org | Laboratory Investigation | Volume 92 August 2012

findings of the differential role of EP4 activity in VEGF-C
and VEGF-D upregulation was validated further by siRNAmediated knockdown (115 nM of siRNA) of EP4 mRNA in
C3L5 cells (Figure 1h). The efficiency of the knock down was
80–85%. VEGF-C and VEGF-D mRNA levels in C3L5 cells
were significantly downregulated by EP4-specific siRNA
treatment as compared with scrambled (control) siRNA
treatment (Figure 1h) or no treatment (indistinguishable
from the former; data not shown).
Therapy with Non-Selective or Selective COX-2
Inhibitors or EP4 Antagonist Inhibits the Growth of
Primary C3L5 Tumors in Syngeneic Mice
Implants of Matrigel alone in a small number (six) of control
mice remained unchanged in size appearing as clear avascular
jelly beans (Figure 2b). The growth of the primary tumors
resulting from tumor cell-inclusive Matrigel implants was
measured by two different methods giving similar results.
The tumor volumes (computed as 0.5  a2 b, from the
minimum (a) and maximum (b) diameters of the retrieved
tumors, data not shown) as well as the weights of fresh
1119
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Figure 2 Therapy with COX-1/2 and COX-2 inhibitors or EP4 antagonist, but not EP1 antagonist reduces primary tumor growth in C3H/HeJ mice. (a)
Representative images of tumor-inclusive Matrigel implants retrieved on day 16 (a scale in mm shown in the background). (b) Image of only Matrigel
implant retrieved on day 16. (c) Mean weights of tumors were reduced significantly in mice treated with indomethacin, celecoxib or EP4 antagonist ONOAE3-208 (EP4A), but not EP1 antagonist ONO-8713 (EP1A), compared with respective vehicle-treated controls. This reduction was significant day 12 with
celecoxib and EP4A, and highly significant on day 16 for all therapies except EP1A. Data represent mean (n ¼ 16 per group per day)±s.e. *Po0.05,
**Po0.005.

unfixed tumors (data shown in Figure 2c, along with gross
morphology of representative tumors in Figure 2a) were
significantly reduced by all therapies except with EP1 antagonist. This reduction was significant at day 12 (Po0.05)
for celecoxib and EP4A treatments and highly significant
(Po0.005) on day 16 for indomethacin, celecoxib and EP4A
treatments, as compared with respective control vehicle
treatments. EP1 antagonist ONO-8713 caused no significant
reduction at any time. None of these drugs had any effect on
the daily water intake (data not shown) excluding any confounding effects of water deprivation. None of the mice at
autopsy (days 8, 12 and 16) exhibited any gastro-intestinal
bleeding indicative of treatment-related toxicity. These data
were highly reproducible in two other pilot experiments,
which had to be terminated on days 18–20, when control
tumor-bearing mice developed tumor-related stress. The
1120

combined data revealed that significant reduction in tumor
growth occurred on days 11–12 and continued until day 20
with indomethacin, celecoxib and EP4A.
Therapy with Non-Selective or Selective COX-2
Inhibitors or EP4 Antagonist Reduced Tumor-Associated
Angiogenesis and Lymphangiogenesis in C3H/HeJ Mice
No measurable angiogenesis or lymphangiogenesis was
observed in tumor cell-exclusive Matrigel implants at any
interval (not shown) confirming our earlier findings on
angiogenesis.36 We additionally found that growth factorreduced Matrigel, on its own, did not stimulate lymphangiogenesis. In Figure 3a, bright field images of Masson’s
Trichrome-stained sections, adjacent to fluorescence microscopy images, are included to show that blood vessels were
most abundant in the peritumoral stroma. The immunoLaboratory Investigation | Volume 92 August 2012 | www.laboratoryinvestigation.org
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Figure 3 Therapy with non-selective or selective COX-2 inhibitors or EP4 antagonist reduced tumor-associated angiogenesis and lymphangiogenesis in
C3H/HeJ mice. (a) Bright field images of Masson’s Tricrome-stained sections (first and third columns) showing peritumoral stroma inclusive of vessels
(scale bars in mm given as insets), and fluorescence images of corresponding tumors representing ‘hot spots’ within the tumors (second and fourth
columns). Tumor-associated angiogenesis (CD31 immuno-staining in red) and lymphangiogenesis (LYVE-1 immuno-staining in green), are shown as
representative fluorescent merged images. There was practically no overlap between the vessels identified by two colors confirming the specificity of
the markers. Therapy with COX-1/2 and COX-2 inhibitors or EP4 antagonist but not EP1 antagonist significantly reduced both angiogenesis and
lymphangiogenesis. Representative images are shown in (a) and quantified as corresponding ‘hot spot’ scores for CD31 and LYVE-1 (b) (n ¼ 16, using the
mean of three hot spots from each of the 16 tumors per group) ±s.e., *Po0.05, **Po0.005.

www.laboratoryinvestigation.org | Laboratory Investigation | Volume 92 August 2012
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fluorescence images are representative of ‘hot spots’ within
the tumors. High levels of tumor-associated angiogenesis as
well as lymphangiogenesis (identified respectively with
CD31 and LYVE-1 immunostaining, shown in merged
pictures in Figure 3a, and quantified in Figure 3b) occurred
in all vehicle-treated mice at all-time points with very little or
no temporal change. A significant reduction of both
events occurred at all-time points with all the therapies
except with the EP1 antagonist. These drug effects (Figure 3)
appeared to precede their growth inhibitory effects on
tumor mass (Figure 2c). For example, reduction in angiogenesis and lymphangiogenesis were noted on day 8, whereas
a reduction in tumor mass was first noted on days 11 and 12
of therapy.

Table 1 Incidence of tumor-positive lymph nodes in different
groups

Inguinal

Day 8

Day 12

Day 16

a

n/N (%)

a

n/N (%)

n/Na (%)

Control

2/4 (50)

4/4 (100)

3/5 (60)

Treatment

3/8 (37.5)

1/5 (20)

0/3 (0)

Control

3/7 (42.9)

5/6 (83.3)

4/5 (80)

Treatment

2/6 (33.3)

1/7 (14.3)

0/6 (0)

Control

3/7 (42.9)

3/4 (75)

2/3 (66.7)

Treatment

1/4 (25)

0/4 (0)

0/4 (0)

Indomethacin

Control

3/9 (33.3)

2/8 (25)

3/4 (75)

Celecoxib

Control

Indomethacin

Celecoxib

EP4A

Axillary

Treatment

Therapies with Non-Selective or Selective COX-2
Inhibitor or EP4 Antagonist Inhibit Regional and Distant
Lymph Node Metastases
As EP1 antagonist was ineffective in reducing tumor growth
or tumor-associated lymphangiogenesis, we refrained from a
laborious histopathological analysis of lymphatic metastasis
in this group. Table 1 summarizes the incidence of lymph
nodes exhibiting histological evidence of metastasis in all
other vehicle- and drug-treated groups.
On pooling the data from all vehicle-treated control mice,
the incidence of tumor-positive inguinal nodes showed an
increase from 44% on day 8 to 85% and 69%, respectively,
on days 12 and 16. For the axillary nodes, this incidence
was 29–38% on days 8 and 12, increasing to 50% on day 16.
All therapies (indomethacin, celecoxib and ONO-AE3-208)
drastically reduced this incidence on day 12, bringing it
down to 0% on day 16. A significant reduction was evident
on day 8, with EP4A. As metastasis at the single cell or
small cell cluster level was not identifiable reliably on
histological grounds, and many putative lymph nodes
showing only tumor cells and no lymph node architecture
were excluded from the analysis, the above incidence can
be considered as minimal in all groups. Figure 4 shows
representative histological pictures in H&E-stained sections
of some of the nodes.
Therapy with COX-1/2 Inhibitor, COX-2 Inhibitor or EP4
Antagonist Reduces Spontaneous Lung Metastasis
Micro-metastases in H&E-stained lung sections were noted
as early as day 8 in control mice (image not presented,
quantification in Figure 5b). Representative images of lung
sections recorded at day 16 are shown in Figure 5a. Figure 5b
shows the median number of metastatic lung colonies at
various times after tumor transplantation. Therapies with
indomethacin, celecoxib and ONO-AE3-208 all significantly
abrogated lung micro-metastases. In contrast, EP1 antagonist
ONO- 8713 did not have any anti-metastatic effect. In fact, it
slightly (but not significantly, P ¼ 0.056) promoted metastases scored on day 12.
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0/7 (0)

0/4 (0)

2/7 (28.6)

4/8 (50)

0/10 (0)

0/7 (0)

0/8 (0)

Control

4/13 (30.8)

1/3 (33.3)

4/10 (40)

Treatment

0/10 (0)

1/6 (16.7)

0/8 (0)

Treatment
EP4A

1/10 (10)
3/9 (33.3)

a

Tumor-positive (n)/total (N); many putative lymph nodes identified at the
gross level had no histological architecture of lymph nodes and were indistinguishable from tumor tissue. These nodes were excluded from the analysis.
Control ¼ respective vehicle-treated mice.

Therapy with COX-1/2 Inhibitor, COX-2 Inhibitor or EP4
Antagonist Reduces the Levels of VEGF-C and VEGF-D
Proteins and Phosphorylated AkT in Residual Tumors,
Concomitant with an Increase in Apoptotic/Proliferative
Cell Ratios
Our in vitro data revealed that the production of the lymphangiogenic factors VEGF-C and VEGF-D by tumor cells
was inhibited with indomethacin, celecoxib and as well as
ONO-AE3-208. As these drugs also reduced tumor growth
and tumor-associated lymphangiogenesis in vivo, we tested
whether there was a concomitant reduction in the levels of
VEGF-C and VEGF-D proteins within the residual tumors
with these therapies. Western blot data in Figure 6 shows that
this was indeed the case. Although an activation of both EP2
and EP4 receptors stimulate the cAMP pathway, EP4 activation also stimulates PI3K/AkT pathway to promote tumor
growth/survival.29,40 For this reason, we tested whether the
cyto-reductive effects of indomethacin, celecoxib and EP4
antagonist therapies, were all associated with reduction of
EP4 activity and thereby a reduction of AkT phosphorylation
in the tumors. Western blot data in Figure 6 and apoptotic/
proliferative cell ratios in Figure 7 confirm this contention.
These ratios were significantly higher in EP4A-treated
mice as compared with vehicle-treated mice at all-time
points. Furthermore, there was a significant temporal
increase in this ratio in EP4A-treated mice, whereas there
was a significant temporal decline in control mice. Data
(not presented) were very similar for indomethacin and
celecoxib-treated mice.
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Figure 4 Therapy with COX-1/2 inhibitor or COX-2 inhibitor or EP4 antagonist abrogated regional and distant lymph node metastasis. Histological
pictures (H&E stained) of representative lymph nodes: Day 8: inguinal nodes in control (vehicle treated) (a, inset magnified fourfold in (b) and EP4A treated
(c, inset magnified fourfold in d) mice. Lymph node in (a) is completely replaced by tumor cells (marked as T) showing the trail of invasion from the
primary tumor on the left. Lymph node in (c) is tumor free. Day 12: nodes in (e, f) show metastatic tumor cells (T), outlined by red markings; lymph nodes in
(g, h) are tumor-free. Day 16: nodes in (i, j) show tumor cells (T), outlined by red markings. Nodes in (k, l) are tumor free. Scale bars for magnification
in images are shown as insets (50 mm for all, except for a and c, 200 mm).

DISCUSSION
Present in vitro studies revealed that high COX-2 expressing
C3L5 breast cancer cells express all the EP receptors and
produce VEGF-C and VEGF-D, both of which could be
downregulated with COX-1/COX-2 or COX-2 inhibitors and
an EP4 antagonist, similar to our findings in COX-2 expressing, VEGF-C producing human breast cancer cell
lines.17 The role of EP4 was further validated with siRNAmediated knockdown. We confirmed our earlier findings that
subcutaneous transplants of C3L5 cells suspended in growth
factor-reduced Matrigel in both inguinal regions of C3H/HeJ
mice provided a robust system for measuring tumor-associated angiogenesis.36 Additionally, we show that system is
also exquisitely suited to measuring tumor-associated lymphangiogenesis and lymphatic metastasis to local and distant
www.laboratoryinvestigation.org | Laboratory Investigation | Volume 92 August 2012

nodes. Although human cancer cell xenografts in immunodeficient mice have been utilized to study tumor-associated
lymphangiogenesis and/or lymphatic metastasis,41,42 to our
knowledge, ours is the first syngeneic breast cancer model in
immune competent mice showing rapid and spontaneous
metastasis of the primary tumor to regional and distant
lymph nodes, mimicking aggressive breast cancer in the human. Using this model, this study demonstrated that an EP4
antagonist ONO-AE3-208, but not EP1 antagonist ONO8713 was highly and equally effective as a COX-2 inhibitor
celecoxib in inhibiting primary tumor growth, tumor-associated angiogenesis and lymphangiogenesis, and metastasis to
the lymph nodes and the lungs. In view of the fact that the
tumor burden was very high because of the dual transplants
in our present tumor model, the observed therapeutic effects
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Figure 5 Therapy with COX-1/2 and COX-2 inhibitors or EP4 antagonist reduces metastatic lung colony formation. (a) Representative images of micro
metastases in H&E-stained lung sections on day 16. They were noted as early as day 8 (data not presented). Scale bar represents 100 mm. (b) Median
numbers of metastatic lung colonies were reduced with all treatments (except EP1A) at all-time points after tumor transplantation. (n ¼ 8 per group per
day). Data represent median±quartile deviations. *Po0.05; **Po0.01.

may possibly be under-estimated in comparison with our
single transplant model used to measure effects of the NOS
inhibitor L-NAME36 and the COX inhibitor indomethacin14
on tumor-associated angiogenesis.
VEGF-C, a key promoter of lymphangiogenesis, was
shown to be upregulated by COX-2 in human breast cancer,17
as also replicated in our present murine model. Although the
role of VEGF-D in breast cancer-associated lymphangiogenesis and lymphatic metastasis has been documented,22 to our
knowledge this is the first study to report the role of COX-2
in upregulating VEGF-D in breast cancer.
The roles of individual EP receptors in tumor development
and progression have so far been shown to vary with the
tumor model and the specific cellular functions contributing
to the cancer progression. Multiple EP receptors have been
implicated in various aspects of breast cancer development
and progression: EP1 in mammary carcinogenesis;43 EP2 in
1124

COX-2-induced mammary hyperplasia;44 EP4 in promoting
invasiveness in an inflammatory type breast cancer cell line.45
We have reported earlier that EP4, and to a smaller extent
EP1 was responsible for both migration-stimulatory15 and
VEGF-C upregulatory17 actions of endogenous PGE2 on
breast cancer cells. In addition to confirming the role of EP4
in VEGF-C production, this study also revealed its role in
VEGF-D upregulation, consistent with the report that an EP4
agonist upregulated VEGF-D in cultured fibroblast cells.46
Taken together, EP4 appears to have a major role in COX-2
actions in breast cancer progression, making it a logical
therapeutic target for intervening breast cancer-associated
lymphangiogenesis and lymphatic metastasis, as validated in
this study. In spite of our earlier findings of participation of
EP1 in breast cancer cell migration15 and VEGF-C upregulation,17 the presently used EP1 antagonist proved to be
ineffective in vivo in our murine breast cancer model.
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Figure 6 Therapy with COX-1/2 inhibitor, COX-2 inhibitor and EP4 antagonist reduces the levels of VEGF-C, -D and phosphorylated AkT proteins in
residual tumors. Total tumor lysate proteins (pooled from eight tumors per group, triplicate measurements) were subjected to western blots for pAkT and
total AkT, VEGF-C and -D and GAPDH proteins. Densitometric measurements of pAkT relative to total AkT, and VEGF-C and -D relative to GAPDH reveal a
significant reduction of all these parameters in the drug-treated groups at all intervals, as compared with vehicle-treated controls. Data represent
mean±s.e., *Po0.05.

This is the first study to demonstrate therapeutic efficacy
of a COX-2 inhibitor or an EP4 antagonist, but not EP1
antagonist in vivo in inhibiting breast cancer-associated
lymphangiogenesis and lymphatic metastasis. In earlier
reports, pharmacological antagonism of EP447 or EP148 by
in vitro treatment of murine breast cancer cell lines with
respective EP antagonists revealed opposing effects on their
lung colony-forming ability on intravenous injection. The
authors concluded that EP4 promoted, whereas EP1 suppressed lung colony-forming ability. They extended the latter
results by downregulating EP1 with shRNA and correlated
the paucity of nuclear EP1 immunostaining with poor survival in breast cancer patients, implicating EP1 as a tumorsuppressor molecule.48 In this study, we noted no significant
effect on spontaneous lung metastasis with the currently
used ONO EP1 antagonist. Nevertheless, these results
should be taken into consideration in developing EP1 anwww.laboratoryinvestigation.org | Laboratory Investigation | Volume 92 August 2012

tagonists for clinical use in patients with potential risk of
breast cancer.
EP4 appears to be a good therapeutic target in a few other
cancer models. For example, treating mice with the present
EP4 antagonist ONO-AE3-208 was shown to reduce experimental lung metastasis of Lewis Lung carcinoma cells given
by the intravenous route and liver metastasis of MC26 colon
carcinoma cells delivered by the intrasplenic route.38 In the
former case, a reduced lung colonization by tumor cells in
EP4 null mice suggested that EP4 expression by tumor as well
as host cells may have contributed to the therapeutic effects
of the EP4 antagonist. In this study, we have not excluded
this possibility. Interestingly, EP4 was shown to be upregulated in human prostate cancer tissues during progression to
castration resistance, and was validated as a potential therapeutic target for treating castration-resistant prostate cancer,
using an EP4 overexpressing prostate cancer xenograft model
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Figure 7 EP4 antagonist therapy increases the apoptotic/proliferative cell ratios in residual tumors. (a) Representative abundance of proliferative cells
labeled for Ki67 marker (red), and apoptotic cells labeled for TUNEL (green) in situ are illustrated in serial sections for day 12 in vehicle-treated (control) and
EP4A-treated mice. Images of corresponding H&E-stained tumors in adjacent sections are shown on the left (scale bars are 50 mm, shown as insets). (b) The
ratios of apoptotic/proliferative cells at different days following vehicle or EP4A therapy. Data represent mean (n ¼ 12)±s.e., *Po0.05.; **Po0.005
comparing the two groups. The ratios showed a significant increase with time in EP4A-treated mice and decrease in control mice.

and therapy with the EP4 antagonist ONO-AE3-208.49 EP4
profiling of human breast cancer tissues is currently in progress in our laboratory to test its possible association with
human breast cancer progression.
Both EP2 and EP4 are linked with a Gs protein and
thus activation of these receptors leads to an increase in
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intracellular cAMP followed by activation of protein kinase
A. In addition, EP4 activation can also stimulate PI3K/AkT
pathway,29 to promote PGE2-dependent cell survival.40
In this study, residual tumors in mice treated with
indomethacin, celecoxib as well as the EP4 antagonist ONOAE3-208 showed a parallel reduction of AkT phosphorylation
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as well as VEGF-C or -D proteins, concomitant with an
increase in apoptotic/proliferative cell ratios. As EP4 is the
only EP receptor known to be linked with AkT activation, we
believe that a blockade in EP4 signaling resulted from all the
afore-mentioned therapies. The cyto-reductive effects of
these therapies on the primary tumor can be attributed to
both direct and indirect effects of the drugs on tumor cells,
mediated by EP4 receptor inactivation: the direct effects,
by blocking PGE2-dependent tumor cell survival;40 and the
indirect effects because of a reduction in blood supply required for tumor cell oxygenation, proliferation and survival.
This contention is supported by the findings that a reduction
in tumor growth was preceded by a reduction in angiogenesis. Similar to the findings that EP4 was instrumental
in stimulating the production of the lymphangiogenic factors
VEGF-C and -D, we suggest that this is also true for the
production of angiogenic factors by tumor cells. Direct effect
of PGE2 on vascular and lymphatic endothelial cells in promoting the processes of angiogenesis and lymphangiogenesis
are additional possibilities. In support, our preliminary data
show that PGE2 produced by the present tumor cell line
stimulates EP4 receptor on lymphatic endothelial cells in
promoting tube formation in vitro.50
Molecular mechanisms responsible for EP4-mediated upregulation of lymphangiogenic factors in breast cancer cells
remains to be investigated. Our preliminary findings reveal
that endogenous PGE2-mediated upregulation of VEGF-C in
the human breast cancer cell line MDA-MB-231 is dependent
on the recruitment of the transcription factor NFkB in the
VEGF-C promoter site.51 It has been shown that EP4mediated activation of PI3K/AkT pathway can cause downstream activation of ERK1/2 to induce the transcription
factor early growth response factor (Efr)-129 that can upregulate VEGF-A in head and neck carcinoma.52 Studies are in
progress to determine whether PI3K/AkT pathway is linked
with EP4-mediated VEGF-C or D upregulation by recruitment of specific transcription factors.
There is compelling epidemiological evidence that intake
of NSAIDs, including COX-2 inhibitors leads to significant
risk reductions for the development of cancers in various
organs including the breast.11,53 As a result of documented
cardiovascular side effects of COX-2 inhibitors,25,26,54 alternative and safer therapies as single agent or in combination
(as adjuvant) need to be tested in preclinical models. Based
on our earlier data on the role of EP4 in multiple cellular
events promoting breast cancer progression, our present
preclinical data, and the fact that EP4 may have some
redundancy for physiological functions shared with EP2, we
suggest that EP4 may prove to be a safe target in the clinic for
preventing and mitigating lymphatic metastasis of breast
cancer in combination with other agents.
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